ROCKVILLE, Md., Jan. 23,
2024 /PRNewswire/ -- Shuttle Pharmaceuticals
Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage
specialty pharmaceutical company focused on improving the outcomes
of cancer patients treated with radiation therapy (RT), today
announced that Dr. Anatoly
Dritschilo, Chief Executive Officer, will participate in a
fireside chat and host one-on-one meetings with investors at the
Lytham Partners 2024 Investor Select Conference, taking place
virtually on February 1, 2024.
At the conference, Dr. Dritschilo will discuss details of the
Company's recent FDA approval to proceed with the Phase II clinical
trial of Ropidoxuridine for treatment of patients with
glioblastoma, as well as other key areas of progress as Shuttle
aims to improve the lives of cancer patients by developing
therapies that are designed to maximize the effectiveness of RT
while limiting the side effects of radiation in cancer
treatment.
Company Webcast
The webcasted fireside chat will take place at 1:15pm ET on
Thursday, February 1, 2024. The
webcast can be accessed at
https://wsw.com/webcast/lytham10/shph/2099184 or on the Company's
website at https://shuttlepharma.com/investor-relations/. The
webcast will also be available for replay following the event.
1x1 Meetings
Management will be participating in virtual one-on-one meetings
throughout the event. To arrange a meeting with management, please
contact Lytham Partners at 1x1@lythampartners.com or register for
the event at https://lythampartners.com/select2024invreg/.
Further information on the conference is available at
https://lythampartners.com/select2024.
About Shuttle Pharmaceuticals
Founded in 2012 by faculty members of the Georgetown
University Medical Center, Shuttle Pharmaceuticals is a
discovery and development stage specialty pharmaceutical company
focused on improving the outcomes for cancer patients treated with
radiation therapy (RT). Our mission is to improve the lives of
cancer patients by developing therapies that are designed to
maximize the effectiveness of RT while limiting the side effects of
radiation in cancer treatment. Although RT is a proven modality for
treating cancers, by developing radiation sensitizers, we aim to
increase cancer cure rates, prolong patient survival and improve
quality of life when used as a primary treatment or in combination
with surgery, chemotherapy and immunotherapy. For more information,
please visit our website at www.shuttlepharma.com.
Shuttle Pharmaceuticals
Anatoly Dritschilo, M.D., CEO
240-403-4212
info@shuttlepharma.com
Investor Contacts
Lytham Partners, LLC
Robert Blum
602-889-9700
shph@lythampartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/shuttle-pharma-to-participate-in-a-fireside-chat-at-the-lytham-partners-2024-investor-select-conference-on-february-1-2024-302042226.html
SOURCE Shuttle Pharmaceuticals Holdings, Inc.